Shares of Vir Biotechnology (NYSE:VIR) have been given a consensus rating of “Buy” by the six ratings firms that are currently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $29.00.

Several analysts recently weighed in on VIR shares. Cowen started coverage on shares of Vir Biotechnology in a report on Tuesday, November 19th. They issued a “buy” rating on the stock. Goldman Sachs Group initiated coverage on shares of Vir Biotechnology in a research note on Tuesday, November 5th. They issued a “buy” rating and a $37.00 price target on the stock. Barclays initiated coverage on shares of Vir Biotechnology in a research note on Tuesday, November 5th. They issued an “overweight” rating and a $25.00 price target on the stock. JPMorgan Chase & Co. initiated coverage on shares of Vir Biotechnology in a research note on Tuesday, November 5th. They issued an “overweight” rating and a $25.00 price target on the stock. Finally, Robert W. Baird initiated coverage on shares of Vir Biotechnology in a research note on Wednesday, November 13th. They issued a “neutral” rating on the stock.

NYSE VIR traded up $1.34 during trading hours on Friday, reaching $16.60. The company had a trading volume of 75,195 shares, compared to its average volume of 103,830. The firm has a 50-day moving average price of $12.67. Vir Biotechnology has a 1-year low of $11.65 and a 1-year high of $16.50.

Vir Biotechnology (NYSE:VIR) last issued its quarterly earnings results on Tuesday, November 19th. The company reported ($4.60) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($3.71) by ($0.89). The firm had revenue of $1.40 million for the quarter.

About Vir Biotechnology

Vir Biotechnology, Inc, a clinical-stage immunology company, develops therapeutic products for the treatment and prevention of serious infectious diseases. It develops VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; VIR-1111 for the prevention of human immunodeficiency virus, and VIR-2020 for the prevention of tuberculosis.

See Also: Diversification For Individual Investors

Analyst Recommendations for Vir Biotechnology (NYSE:VIR)

Receive News & Ratings for Vir Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vir Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.